Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 1,818.00
-29.00 (-1.57%)
Aug 4, 2026, 10:04 AM JST
Fuji Pharma Financials Overview
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Revenue Revenue Growth | 57,298 | 51,677 | 46,138 | 40,889 | 35,426 | 33,990 |
Revenue Growth | 17.31% | 12.01% | 12.84% | 15.42% | 4.23% | 0.58% |
Gross Profit Gross Profit Growth | 23,207 | 20,763 | 17,844 | 16,515 | 14,559 | 14,751 |
Operating Income Operating Income Growth | 7,083 | 4,990 | 3,881 | 3,859 | 3,778 | 3,349 |
Net Income Net Income Growth | 2,426 | 3,000 | 6,146 | 3,435 | 2,696 | 2,432 |
Earnings Per Share EPS Growth | 98.53 | 122.93 | 252.81 | 141.35 | 110.98 | 90.52 |
EPS Growth | -24.48% | -51.37% | 78.86% | 27.37% | 22.60% | 35.27% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Investments Cash & Investments Growth | 10,887 | 7,245 | 4,585 | 2,324 | 3,546 | 10,199 |
Total Debt Total Debt Growth | 29,616 | 30,937 | 29,254 | 28,948 | 24,569 | 18,662 |
Net Cash (Debt) Net Cash Growth | -18,729 | -23,692 | -24,669 | -26,624 | -21,023 | -8,463 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -760.70 | -970.86 | -1014.74 | -1095.58 | -865.39 | -315.00 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 7,730 | 5,801 | 4,151 | 1,917 | -658 | 5,993 |
Capital Expenditures CapEx Growth | -2,222 | -1,981 | -2,778 | -3,327 | -5,097 | -3,789 |
Free Cash Flow Free Cash Flow Growth | 5,508 | 3,820 | 1,373 | -1,410 | -5,755 | 2,204 |
Free Cash Flow Growth | 6.58% | 178.22% | - | - | - | -36.08% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Gross Margin | 40.50% | 40.18% | 38.67% | 40.39% | 41.10% | 43.40% |
Operating Margin | 12.36% | 9.66% | 8.41% | 9.44% | 10.66% | 9.85% |
Pretax Margin | 5.12% | 7.74% | 17.93% | 10.76% | 10.51% | 9.91% |
Profit Margin | 4.23% | 5.80% | 13.32% | 8.40% | 7.61% | 7.16% |
FCF Margin | 9.61% | 7.39% | 2.98% | -3.45% | -16.25% | 6.48% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Dividend Per Share Dividend Per Share Growth | 49.000 | 45.500 | 42.500 | 37.000 | 35.000 | 29.000 |
Dividend Per Share Growth | 7.69% | 7.06% | 14.87% | 5.71% | 20.69% | 0% |
Dividend Yield | 2.63% | 2.97% | 3.47% | 3.40% | 3.74% | 2.84% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
PE Ratio | 18.74 | 12.57 | 5.04 | 8.25 | 9.32 | 11.68 |
Forward PE | 12.53 | 10.31 | 7.24 | 8.29 | 8.47 | 12.03 |
P/FCF Ratio | 8.76 | 9.87 | 22.54 | - | - | 12.89 |
PS Ratio | 0.84 | 0.73 | 0.67 | 0.69 | 0.71 | 0.84 |